An in-depth interpretation of the instructions for deuterated colexitinib

Deucravacitinib is an innovative oral tyrosine kinase 2 (TYK2) inhibitor. As the world's first and currently only drug that selectively targets TYK2, it was first approved by the US FDA in 2022 for the treatment of adult patients with moderate to severe plaque psoriasis (Plaque Psoriasis). Its unique molecular mechanism and relatively good safety make it stand out among many treatment methods, and also provides a new treatment option for patients who need systemic treatment or phototherapy.

From a mechanism perspective, deuterated coxitinib is different from traditionalJAK inhibitors. It does not directly inhibit JAK1/2/3, but blocks the activation of pro-inflammatory signaling pathways such as IL-23, IL-12 and type I interferon by targeting the regulatory domain of TYK2 (pseudokinase domain). Because it does not interfere with other JAK pathways, it is more selective and theoretically has fewer side effects. Multiple overseas Phase III clinical trials (including POETYK PSO-1 and PSO-2 studies) have confirmed that the drug is significantly better than placebo and active control drugs (such as Apremilast) in improving psoriasis lesions, while the adverse reaction rate is relatively lower.

In terms of usage and dosage, according to the instructions approved by the FDA in the United States, the recommended dose of deuterated colexitinib is 6 mg per time, taken orally once a day, and does not need to be taken with food or dose escalation. It is worth mentioning that no dose adjustment is required in patients with mild to moderate hepatic impairment, but it is clearly contraindicated in patients with severe hepatic impairment, which is inferred based on pharmacokinetic data that the drug is mainly metabolized by the liver. Therefore, liver function evaluation must be performed before treatment, and liver enzyme indicators should be monitored regularly if necessary.

Regarding safety issues, the tolerability of deuterated colexitinib has been good in existing clinical trials. The most common side effects include upper respiratory tract infection, nasopharyngitis, headache, acne and diarrhea, most of which are mild to moderate and can resolve spontaneously. Unlike traditional JAK inhibitors, this drug has not been found to significantly increase the risk of venous thrombosis, malignant tumors or serious infections. However, because it acts on the immune system, the instructions still recommend checking for active or potential infections (such as tuberculosis, hepatitis B) before taking the drug, and regularly testing blood routine and liver function indicators to ensure drug safety.

In addition, deuterated colexitinib is not recommended for use in pregnant and lactating women. Current research data on pregnancy risks are limited, and certain embryotoxicity has only been observed in animal studies. Therefore, the pros and cons should be carefully weighed in clinical use. For women who plan to have children, they should fully communicate with their doctor before taking the medicine and take effective contraceptive measures if necessary.

Overseas guidelines point out that deuterated colexitinib is particularly suitable for psoriasis patients who have poor response to traditional treatments, cannot tolerate phototherapy, or are unwilling to inject biological agents. At the same time, its oral delivery method also greatly improves compliance and patient satisfaction. Compared with TNF or IL inhibitory biological agents that require injection, this drug has an advantage in convenience of use, and its efficacy is comparable to some biological agents, especially in terms of PASI75 and sPGA response rates.

Overall, the launch of deuterated colexitinib marks that the field of psoriasis treatment has entered a new stage that is more precise, safe and convenient. As the first selective TYK2 inhibitor, it not only expands the toolbox of clinical treatment, but also heralds the development direction of more targeted oral drugs. In future clinical practice, how to better conduct individualized combined treatment with traditional systemic drugs, biological agents or phototherapy may become a focus of research.

Reference materials:https://go.drugbank.com/drugs/DB16650